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Summary This prospective open-label study used ﬂexible dosing schedules of lev-
etiracetam (LEV) in patients with refractory epilepsy attending a single centre to
explore its effectiveness in everyday clinical practice.
One hundred and ﬁfty-six patients with uncontrolled localisation-related or idio-
pathic-generalised epilepsy were prescribed adjunctive LEV following a 3-month base-
line. The primary end points were seizure freedom for at least 6 months, ≥50%
reduction (responder) or <50% reduction for 6 months, or discontinuation of LEV
due to lack of efﬁcacy, adverse effects or both.
Overall, 40 (26%) patients became seizure free on adjunctive LEV, including 8 (40%)
with idiopathic-generalised epilepsy. Twenty-ﬁve (63%) of the seizure-free patients
took 1000mg LEV per day or less. A further 33 (21%) patients were classiﬁed as re-
sponders.
LEV was withdrawn in 46 (29%) patients (27 adverse effects, 8 lack of efﬁcacy,
11 both). Intolerable sedation, reported by 20 (13%) patients, was the commonest
complaint leading to treatment failure. Behavioural side effects led to LEV withdrawal
in 7 (5%) patients.
LEV is an effective adjunctive treatment for refractory idiopathic and localisation-
related epilepsies. Many patients who responded optimally to LEV did so at 1000mg
per day or less.
© 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Levetiracetam (LEV) is a novel antiepileptic drug
(AED), which was licensed in the UK in November
2000 as an adjunctive treatment for partial seizures
with or without secondary generalisation. Its
mechanisms of action appear different from other
AEDs.1 LEV binds to a speciﬁc membrane-binding
site in the brain.2 It does not affect glutamate
or gamma aminobutyric acid-mediated synaptic




transmission,3,4 nor does it modulate voltage de-
pendent sodium or T-type calcium currents.5 LEV
showed no efﬁcacy in maximal electroshock and
chemoconvulsive seizure models,6 but markedly
suppressed seizures in kindled and genetically
epileptic animals.7,8 Its pharmacokinetic charac-
teristics have been described as close to ideal.9 LEV
has high oral bioavailability unaffected by food,
exhibits linear kinetics, is not signiﬁcantly bound to
plasma proteins, is largely excreted unchanged by
the kidneys, and is not prone to pharmacokinetic
drug interactions.
The efﬁcacy of LEV has been assessed in placebo-
controlled randomised trials which demonstrated
reduction in seizure numbers and improved quality
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of life in patients with partial seizures with or with-
out secondary generalisation.10—14 Post-marketing
studies have suggested that LEV may also be efﬁ-
cacious for idiopathic-generalised epilepsies.15—17
Randomised-controlled trials carried out to meet
regulatory requirements provide little information
to guide pharmacological decision-making in clin-
ical practice.18 Pragmatic open-label studies in
the post-marketing phase employing ﬂexible dos-
ing schedules will allow the effectiveness of an
AED to be assessed in ‘‘real life’’ situations. We
conducted a single centre, prospective, open-label
study of adjunctive LEV in patients with uncon-
trolled seizures to assess its utility for a variety of
seizure disorders in everyday clinical practice.
Methods
One hundred and ﬁfty-six patients (70 males,
86 females; median age 38 years, range 16—78
years) attending the Epilepsy Clinic at the West-
ern Inﬁrmary in Glasgow, Scotland with uncon-
trolled epilepsy of any type were recruited into
the study. One hundred and thirty-six patients had
localisation-related epilepsy (119 partial and sec-
ondary generalized seizures, 17 partial seizures
only) and 20 had idiopathic generalized epilepsy
(11 juvenile myoclonic epilepsy, 5 typical absences
and tonic—clonic seizures, 4 tonic—clonic seizures
only). Patients had already failed treatment with a
median of three AEDs (range 1—9). Seventy-seven
(49%) patients were taking 1, 68 (44%) 2, 10 (6%) 3
and 1 (1%) patient 4 concomitant AEDs at the time
of entry into the study.
Patients underwent baseline evaluation for 3
months, during which seizure types and frequen-
cies were recorded and AED schedules remained
unchanged. Median seizure frequency during the
baseline period was 5 per month (range 1 to 120
per month). Patients were reviewed by the same
clinician every 6 weeks or sooner if required. Stan-
dard forms were used to collect seizure numbers
and document adverse effects.
Three starting doses were employed in the study.
The manufacturer’s recommended schedule of
500mg twice daily was used in 58 patients, 500mg
once daily was prescribed for 49 patients and the
remaining 49 patients took an initial 250mg LEV
once daily. Dosage modiﬁcations were made in in-
crements of 250—500mg daily every 2—4 weeks
depending on clinical response and adverse effects.
When seizure freedom was attained at any dose,
no further modiﬁcation was made to the regimen.
Withdrawal of concomitant AEDs was attempted
in seizure-free patients only if the combined drug
burden was thought to be responsible for intolera-
ble adverse effects.
The primary end points were seizure freedom
for at least 6 months on an unchanged dose of
LEV, ≥50% reduction (responder) or <50% reduc-
tion (marginal effect) in monthly seizure frequency
for 6 months compared to baseline at maximally
tolerated LEV doses, or discontinuation of LEV
due to lack of efﬁcacy, adverse effects or both.
Data were analysed using Minitab for Windows sta-
tistical software. Proportions were expressed as
percentages. Ranges were quoted with medians
or means and standard deviations as appropri-
ate. The Mann-Whitney test was used to compare
non-parametric continuous data and χ2 test was
used for categorical data.
Results
Overall, 40 (26%) of the 156 patients became
seizure free for a minimum of 6 months on an un-
changed dose of LEV and a further 33 (21%) could
be classed as responders. AED combinations in the
seizure-free patients are listed in Table 1. No par-
ticular combination appeared more efﬁcacious or
more likely to cause adverse effects than the oth-
ers. Thirty-seven (24%) patients reported <50% in
seizure frequency, but elected to continue treat-
ment with the drug. LEV was withdrawn in 46 (29%)
patients, 27 (17%) because of adverse effects, 8





LEV monotherapy 1 LEV








Three other AEDs 1 LEV/CBZ/CLB/TPM
1 LEV/LTG/TPM/VPA
Four other AEDs 1 LEV/AZM/LTG/PB/VPA
Abbreviations: AEDs, antiepileptic drugs; LEV, lev-
etiracetam; CBZ, carbamazepine; VPA, sodium val-
proate; LTG, lamotrigine; GBP, gabapentin; TPM, top-
iramate; CLB, clobazam; AZM, acetazolamide; PB,
phenobarbital.
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Figure 1 Daily levetiracetam doses in each outcome group. Responder ≥50% seizure reduction. Marginal effect <50%
seizure reduction.
(5%) due lack of efﬁcacy, and 11 (7%) due to a
combination of lack of efﬁcacy and side effects.
There was no correlation between LEV doses and
clinical responses (Fig. 1). The median daily doses
in the four main outcome groups were: 1000mg in
seizure-free patients, 2000mg in responders and in
patients reporting a <50% seizure reduction, and
1500mg in patients in whom LEV was withdrawn.
Interestingly, 25 (63%) of the 40 patients who be-
came seizure free with adjunctive LEV were taking
1000mg per day or less with 8 being controlled on
just 500mg daily.
Outcomes by type of epilepsy are shown in
Table 2. Patients with idiopathic-generalised
epilepsy appeared to respond to adjunctive LEV
with 40% becoming seizure free and a further 25%
Table 2 Outcomes in different seizure types and epilepsy syndromes.
Seizure free Responder Marginal effect Withdrawn Total
Idiopathic-generalised epilepsies 8 5 5 2 20
Juvenile myoclonic epilepsy 5 3 3 0 11
Absences ± tonic—clonic seizures 2 2 1 0 5
Generalised tonic—clonic seizures only 1 0 1 2 4
Localisation-related epilepsies 32 28 32 44 136
Partial seizures only 2 4 3 8 17
Partial seizures with secondary generalisation 30 24 29 36 119
Grand total 40 33 37 46 156
Responder: ≥50% seizure reduction vs. baseline. Marginal effect: <50% seizure reduction vs. baseline.
being classiﬁed as responders. Juvenile myoclonic
epilepsy (n = 11) was the most common syndrome
in this cohort with ﬁve of these patients attaining
seizure freedom. Three patients were converted
to LEV monotherapy. One remained seizure free,
while another developed adverse effects and had
LEV withdrawn. The third patient reported only a
marginal response to LEV, but had an improved side
effect proﬁle and elected to continue treatment.
Of the 46 patients in whom LEV was withdrawn,
38 reported adverse effects (Table 3). Sedation
(n = 20) was the commonest complaint leading to
failure of LEV treatment. Behavioural problems in-
cluding aggression, depression, emotional lability
and emergence of post-ictal psychosis and hallu-
cinations were reported by eight patients and led
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Emotional lability 1 1
Episodic leg weakness 1 1
Post-ictal psychosis 1 1
Hallucinations 1 1




Total number of patients* 50 38
* Some patients reported more than one side effect.
to LEV withdrawal in seven of these. Four patients
with localisation-related epilepsy reported worsen-
ing of seizures. Treatment with LEV did not demon-
strate an overall effect on body weight. While
individual patients gained and lost weight over the
course of the study (range −6.2 to +6.4 kg), the
mean change in the entire cohort was +0.09 kg
(S.D.± 2.03 kg). No signiﬁcant differences in the
incidence of adverse effects or withdrawal rates
Figure 2 Actuarial estimate of time to withdrawal.
were observed with the three different starting
doses. Overall, 71% patients continued on treat-
ment with LEV (Fig. 2).
Discussion
There are convincing epidemiological data to sug-
gest that more than 30% of patients with newly diag-
nosed epilepsy never achieve lasting remission with
currently available AEDs.19—22 There is, therefore,
a clear need for new AEDs with novel mechanisms
of action.23 With its unique pharmacological pro-
ﬁle LEV offers a valuable addition to the therapeu-
tic armamentarium for the treatment of refractory
epilepsy.24 Data from open-label pragmatic stud-
ies will enable the most effective dose ranges and
titration schedules to be identiﬁed.
LEV appeared to be highly efﬁcacious with 26% of
our patients achieving complete control of seizures
for 6 months or more. The doses producing seizure
freedom were generally modest with 63% of pa-
tients responding to 1000mg per day or less. This
was signiﬁcantly lower than those noted in the other
outcome groups, suggesting that LEV or AED com-
binations containing LEV may have had a speciﬁc
effect on the epileptic process in these individuals.
We attempted withdrawal to LEV monotherapy in
just three patients, one of whom remained seizure
free.
Patients with idiopathic generalized epilepsy ap-
peared to respond to adjunctive LEV with 40% be-
coming seizure free. Those with juvenile myoclonic
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epilepsy fared especially well with 45% achieving
seizure freedom. Previous treatment with a median
of three AEDs had failed to control myoclonic jerks
and tonic—clonic seizures in these patients. These
results suggest that LEV could be a useful agent for
the treatment of myoclonic syndromes.
Overall, 17% patients developed adverse effects
requiring discontinuation of LEV and a further 12%
had the drug withdrawn after titration due to a
combination of lack of efﬁcacy and side effects.
Sedation was the most common complaint. How-
ever, 5% patients developed behavioural problems
requiring withdrawal of LEV. These included ag-
gression, depression, mood swings, hallucinations,
and post-ictal psychosis, all of which have been
reported previously with this drug.25
Conclusions
LEV has the potential to produce seizure freedom
in a signiﬁcant proportion of patients with hitherto
refractory epilepsy. Sedation and the emergence of
behavioural problems were the main side effects
leading to LEV discontinuation.
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